LEXINGTON, Mass., Nov. 25, 2015 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health, today announced that John McDonough, president and chief executive officer, and Moe Castonguay, chief financial officer, are scheduled to attend and present at the following upcoming investor conferences:

• The Piper Jaffray Healthcare Conference on Wednesday, December 2, 2015 at 10 a.m. ET in New York City.
• The Evercore ISI MedTools & Outsourcing Forum on Thursday, December 3, 2015 in New York City.

A live, listen-only webcast of the Piper Jaffray presentation may be accessed by visiting the Events & Presentations section of the Company's website at www.t2biosystems.com under Investors & Press. A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the Company's website for 30 days following the presentation.  The Evercore Forum is 1x1 meetings only with no webcasting available.

About T2 Biosystems

T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. The T2Candida Panel was cleared for marketing by the U.S. Food and Drug Administration (FDA) in September 2014 for the detection of sepsis causing Candida. T2Candida Panel performance was established in adult subjects. T2Candida Panel performance in neonates, infants, and pediatric patients has not been established. For more information, please visit www.t2biosystems.com.

Media Contact:
Susan Heins, Pure Communications          
susan@purecommunicationsinc.com          
864.286.9597

Investor Contact:
Matt Clawson, Pure Communications
matt@purecommunicationsinc.com 
949-370-8500

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.